

OAKLAND UNIVERSITY WILLIAM BEAUMONT

¹Oakland University William Beaumont School of Medicine, ²Department of Urology, Beaumont Royal Oak

Introduction

-Sacral neuromodulation (SN) and intradetrusor botulinum toxin (BTX) are effective treatments for refractory overactive bladder (OAB) and urge incontinence (UI).¹

-Treatment decisions are based on several factors.

-Urodynamics (UDS) have not been proven to determine who will respond to SN, but results could help guide treatment decisions

-Specifically, detrusor overactivity (DO) suggests that BTX may be more effective, given its direct role on muscle.

-The purpose of this study is to determine if presence and severity of DO on UDS is associated with failure of SN and response to BTX.

Aims and Objectives

-To determine whether DO on urodynamics predicts poor symptom improvement with sacral neuromodulation.

-To determine if other urodynamic findings are predictive of poor symptom improvement with sacral neuromodulation

This is a retrospective review of patients with OAB and UI who failed SN and were subsequently treated with BTX, with complete UDS for review. All UDS were performed off OAB medication, and prior to the first BTX injection or greater than 6 months following the most recent injection. Tracings with or without fluoroscopy were reviewed by a single clinician for presence of DO, bladder volume at first DO, presence of urine leak, max DO amplitude, stress incontinence, and maximum cystometric capacity (MCC).





Figure 1. Flow chart of study cohort selection, inclusion criteria, and the outcome of interest.

Urodynamic Characteristics of Patients with Urge Incontinence treated with Sacral Neuromodulation and Adjunct Botulinum Toxin Injection Brent Yelton¹, Jason Gilleran²

Methods

Outcome: UDS findings that were predictive of SN failure and success with BTX injections

Results

We identified 53 subjects (39 female, mean age 66.2 y) who underwent SN (50 sacral, 9 pudendal) between 2007-2021. Mean time from implant to first BTX was 32.1 months (range 3-90). Mean total BTX injections was 3.4 (1-14). DO occurred on 40/53 (75.4%) and with leak in 32/53 (60.3%) of UDS. Stress leak occurred in only 3 subjects. Mean volume at first DO of 166.4 mL (13-581), and mean MCC was 295.6 mL (81-643). Mean amplitude at first DO was 38.3 cm H2O, and maximum DO amplitude was 52.3 cm H2O.

tudy size	n = 53
Average age	66.2 years
Female (male)	39 (14)
Sacral neuromodulation (pudendal)	50 (9)
Mean Botulinum injections (range)	3.4 (1-14)
Table 2 Summary of the main findings from urodynamic studies	in our population of interest
Fable 2. Summary of the main findings from urodynamic studies	in our population of interest
Table 2. Summary of the main findings from urodynamic studies	in our population of interest
Table 2. Summary of the main findings from urodynamic studies Wean time from SN to first BTX injection	in our population of interest 32.1 months
Table 2. Summary of the main findings from urodynamic studies Mean time from SN to first BTX injection	in our population of interest 32.1 months
Table 2. Summary of the main findings from urodynamic studies Mean time from SN to first BTX injection Percentage of patients with DO present on UDS	in our population of interest 32.1 months 75.4%
Table 2. Summary of the main findings from urodynamic studies Wean time from SN to first BTX injection Percentage of patients with DO present on UDS	in our population of interest 32.1 months 75.4%
Fable 2. Summary of the main findings from urodynamic studies Mean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS	in our population of interest 32.1 months 75.4%
Table 2. Summary of the main findings from urodynamic studies Mean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS	in our population of interest 32.1 months 75.4% 60.3%
Table 2. Summary of the main findings from urodynamic studies Wean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS	in our population of interest 32.1 months 75.4% 60.3%
Fable 2. Summary of the main findings from urodynamic studies Mean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS	in our population of interest 32.1 months 75.4% 60.3%
Fable 2. Summary of the main findings from urodynamic studies Mean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS	in our population of interest 32.1 months 75.4% 60.3%
Table 2. Summary of the main findings from urodynamic studies Wean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS Percentage of patients with Stress incontinence on UDS	in our population of interest 32.1 months 75.4% 60.3% 5.6%
Fable 2. Summary of the main findings from urodynamic studies Wean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS Percentage of patients with Stress incontinence on UDS	in our population of interest 32.1 months 75.4% 60.3% 5.6%
Table 2. Summary of the main findings from urodynamic studies Wean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS Percentage of patients with stress incontinence on UDS Percentage of patients with stress incontinence on UDS	in our population of interest 32.1 months 75.4% 60.3% 5.6% 166.4ml
Fable 2. Summary of the main findings from urodynamic studies Wean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS Percentage of patients with Stress incontinence on UDS	in our population of interest 32.1 months 75.4% 60.3% 5.6% 166.4mL
Fable 2. Summary of the main findings from urodynamic studies Wean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS Percentage of patients with DO with urine leak present on UDS Percentage of patients with stress incontinence on UDS Wean Volume at first DO	in our population of interest 32.1 months 75.4% 60.3% 5.6% 166.4mL
Table 2. Summary of the main findings from urodynamic studies Wean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS Percentage of patients with Stress incontinence on UDS Percentage of patients with stress incontinence on UDS Wean Volume at first DO Wean MCC	in our population of interest 32.1 months 75.4% 60.3% 5.6% 166.4mL 295.6mL
Fable 2. Summary of the main findings from urodynamic studies Wean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS Percentage of patients with Stress incontinence on UDS Wean Volume at first DO Wean MCC	in our population of interest 32.1 months 75.4% 60.3% 5.6% 166.4mL 295.6mL
Fable 2. Summary of the main findings from urodynamic studies Wean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS Percentage of patients with Stress incontinence on UDS Wean Volume at first DO Wean MCC	in our population of interest 32.1 months 75.4% 60.3% 5.6% 166.4mL 295.6mL 38.3 mm H2Q
Fable 2. Summary of the main findings from urodynamic studies Wean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS Percentage of patients with Stress incontinence on UDS Wean Volume at first DO Wean MCC Wean amplitude of first DO	in our population of interest 32.1 months 75.4% 60.3% 5.6% 166.4mL 295.6mL 38.3 mm H2O
Fable 2. Summary of the main findings from urodynamic studies Mean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS Percentage of patients with bo with urine leak present on UDS Percentage of patients with stress incontinence on UDS Wean Volume at first DO Mean amplitude of first DO	in our population of interest 32.1 months 75.4% 60.3% 5.6% 166.4mL 295.6mL 38.3 mm H2O
Table 2. Summary of the main findings from urodynamic studies Vlean time from SN to first BTX injection Percentage of patients with DO present on UDS Percentage of patients with DO with urine leak present on UDS Percentage of patients with Stress incontinence on UDS Vlean Volume at first DO Vlean MCC Vlean amplitude of first DO Vlaximum DO amplitude	in our population of interest 32.1 months 75.4% 60.3% 5.6% 166.4mL 295.6mL 38.3 mm H2O 52.3 mm H2O

Conclusions

The presence of DO at high amplitude (>25 cm H2O) and with leak on UDS is associated with worse UI that does not respond to SN monotherapy



Figure 2. Image demonstrating the technique for intradetrusor botulinum injections

References

Gormley, E. A. et al. (2015) 'Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment', Journal of Urology. Elsevier Inc., 193(5), pp. 1572–1580. doi: 10.1016/J.JURO.2015.01.087.

Shepherd, J. P. et al. (2011) 'InterStim Sacral Neuromodulation and Botox Botulinum-A Toxin Intradetrusor Injections for Refractory Urge Urinary Incontinence: A Decision Analysis Comparing Outcomes Including Efficacy and Complications', *Female pelvic medicine & reconstructive surgery*. Female Pelvic Med Reconstr Surg, 17(4), pp. 199–203. doi: 10.1097/SPV.0B013E318224E0D7.

Acknowledgements

Thank you to Dr. Gilleran and Dr. Baxa for your mentorship throughout this process.











